Conference Reports for NATAP

The International Liver Congress™ EASL - European Association for the Study of the Liver June 22-26 2022 Back

EASL 2022 HBV, HDV Wrap-Up       EASL: Evaluation of Global Progress towards HBV and HCV elimination - off track - (06/23/22)   excerpts on only HBV & HDV from Dr Pawlotsky full talk including HCV. EASL: Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection: interim results from the randomised Phase 2b B-Clear study - (06/26/22) EASL: Therapeutic Vaccine JNJ-0535 Induces a Strong HBV-specific T-cell Response in Healthy Adults and a Modest Response in Chronic HBV-infected Patients VOX/VEL/SOF Effective Rescue After DAA Failure-With Limits - (06/26/22)   EASL: Efficacy and Safety of Finite 48-week Treatment With the siRNA JNJ-3989 and the Capsid Assembly Modulator JNJ-6379 in HBeAg Negative Virologically Suppressed Chronic Hepatitis B Patients: Results from the REEF-2 Study - (06/25/22)